GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker
Just four months after promising a speedy review for using GlaxoSmithKline’s Zejula in late-line ovarian cancer, the FDA has come through with an OK.
The approval arrived just ahead of GSK’s Q3 numbers, backing up R&D chief Hal Barron’s lofty ambitions for the PARP inhibitor. Zejula was the crown jewel in the pharma giant’s $5 billion acquisition of Tesaro, with Barron elbowing to encroach on the blockbuster terrain AstraZeneca and Merck mapped with a market-leading Lynparza in what he calls an under-appreciated class.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,500+ biopharma pros reading Endpoints daily — and it's free.